Brain

Global Alzheimer’s Platform Foundation Announces Strategic Collaboration and Partnership with IXICO for the Transformative Bio-Hermes-002 Study

IXICO joins collaborative study of new biomarkers designed to improve diagnosis of Alzheimer's disease and dementiasWASHINGTON, July 22, 2025 (GLOBE...

ArriVent’s Topline Pivotal Phase 3 FURVENT Data for Firmonertinib in First-Line NSCLC EGFR Exon20 Insertion Mutations is Projected to be Early 2026

Enrollment in FURVENT was completed in Q1 2025 Firmonertinib received FDA Breakthrough Therapy Designation in this patient population NEWTOWN SQUARE,...

Cognition Therapeutics Publishes Proteomic Analysis Elucidating Zervimesine’s Protection of Neurons and Synapses in Alzheimer’s Disease

In Vitro Experiments Showing Protection of Neurons under Disease Conditions Support Proteomics Biomarker Analysis from Phase 2 SEQUEL StudyPITTSBURGH, July...

Axsome Therapeutics Hosts Frontiers in Brain Health R&D Day Reviewing Industry-Leading Late-Stage CNS Pipeline

Comprehensive review of broad pipeline targeting Alzheimer’s disease agitation, depression, narcolepsy, fibromyalgia, ADHD, and smoking cessation, with new data analyses...

Helius Announces Positive Outcome of the Portable Neuromodulation Stimulator PoNS® Stroke Registrational Program and Upcoming Submission to FDA Under Breakthrough Designation

NEWTOWN, Pa., July 21, 2025 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (NASDAQ: HSDT), a neurotech company focused on delivering...

Neurogen Biomarking to present novel data on at-home p-tau 217 testing for Alzheimer’s disease at Alzheimer’s Association International Conference® 2025

CHICAGO, July 17, 2025 (GLOBE NEWSWIRE) -- Neurogen Biomarking will present novel data on at-home p-tau 217 testing for Alzheimer’s...

error: Content is protected !!